Editas Medicine, Inc. (EDIT): Price and Financial Metrics


Editas Medicine, Inc. (EDIT): $39.51

0.05 (+0.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EDIT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

EDIT Stock Summary

  • The ratio of debt to operating expenses for Editas Medicine Inc is higher than it is for about merely 13.33% of US stocks.
  • With a price/sales ratio of 29.3, Editas Medicine Inc has a higher such ratio than 92.05% of stocks in our set.
  • Revenue growth over the past 12 months for Editas Medicine Inc comes in at 341.93%, a number that bests 98.09% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to EDIT, based on their financial statements, market capitalization, and price volatility, are SRPT, ALPN, STRO, SRRK, and SGMO.
  • EDIT's SEC filings can be seen here. And to visit Editas Medicine Inc's official web site, go to www.editasmedicine.com.

EDIT Stock Price Chart Interactive Chart >

Price chart for EDIT

EDIT Price/Volume Stats

Current price $39.51 52-week high $99.95
Prev. close $39.46 52-week low $21.41
Day low $38.25 Volume 426,701
Day high $40.69 Avg. volume 2,485,791
50-day MA $49.09 Dividend yield N/A
200-day MA $42.98 Market Cap 2.66B

Editas Medicine, Inc. (EDIT) Company Bio


Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.


EDIT Latest News Stream


Event/Time News Detail
Loading, please wait...

EDIT Latest Social Stream


Loading social stream, please wait...

View Full EDIT Social Stream

Latest EDIT News From Around the Web

Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.

An End to This Rare Syndrome Could Be an Opportunity for Investors

A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.

Yahoo | April 7, 2021

Here's the Holy Grail of Gene Editing

In this video from Motley Fool Live, recorded on March 15, Fool.com contributors Brian Orelli and Keith Speights discuss the difference between ex vivo gene editing (outside the body) and in vivo editing (within the patient). CRISPR Therapeutics (NASDAQ: CRSP) and its partner Vertex Pharmaceuticals (NASDAQ: VRTX) have mastered ex vivo gene editing, but the strategy is limited to diseases where cells can be manipulated outside the body. Up-and-coming gene editing companies may have a bigger opportunity if they can master the in vivo technique.

Yahoo | April 2, 2021

3 Stocks More Than 25% Off Their 2021 Highs That Could Still Make You Rich

You've no doubt heard the investing adage to "buy the dip." But what if the dip is a really bad one? Sometimes buying stocks that fall significantly isn't such a great idea. On the other hand, there are other cases where scooping up shares when they've retreated a lot can pay off in a big way over the long run.

Yahoo | March 29, 2021

Why Is Editas (EDIT) Down 9.6% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 27, 2021

Booming CAGR of 20.8%, CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc

A new market study on the 2020-2027 CRISPR and CAS Gene Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report

OpenPR | March 23, 2021

Read More 'EDIT' Stories Here

EDIT Price Returns

1-mo -14.63%
3-mo -47.32%
6-mo 22.85%
1-year N/A
3-year 13.89%
5-year 3.46%
YTD -43.65%
2020 136.78%
2019 30.15%
2018 -25.97%
2017 89.34%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0582 seconds.